A substantial proportion of AML patients harbor mutations that cause hyperactivation of JAK-STAT signaling [147]; therefore, great effort has been put into the development of inhibitors that block phosphorylation mediated by JAKs, which have already been shown to efficiently achieve indirect STAT inhibition [86]. Here, SOAT1 is linked to acute myeloid leukemia.